Obesity, inflammation, and insulin resistance

被引:1338
作者
Shoelson, Steven E.
Herrero, Laura
Naaz, Afia
机构
[1] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA
关键词
D O I
10.1053/j.gastro.2007.03.059
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Weight gain and obesity are major risk factors for conditions and diseases ranging from insulin resistance and type 2 diabetes mellitus to atherosclerosis and the sequelae of nonalcoholic fatty liver disease. A chronic, subacute state of inflammation often accompanies the accumulation of excess lipid in adipose tissue and liver (hepatic steatosis), evidenced by changes in both inflammatory cells and biochemical markers of inflammation. These changes can be seen in the involved tissues and systemically, in terms of elevated circulating levels of inflammatory markers. The link between obesity and inflammation has therefore raised the important question of whether obesity-induced inflammation plays a pathogenic role in the development and progression of these disorders. We review the rapidly expanding body of animal and clinical data that support potential roles for inflammation in the pathogenesis of insulin resistance and type 2 diabetes mellitus.
引用
收藏
页码:2169 / 2180
页数:12
相关论文
共 137 条
  • [1] Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action
    Aguirre, V
    Werner, ED
    Giraud, J
    Lee, YH
    Shoelson, SE
    White, MF
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (02) : 1531 - 1537
  • [2] The c-Jun NH2-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser307
    Aguirre, V
    Uchida, T
    Yenush, L
    Davis, R
    White, MF
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (12) : 9047 - 9054
  • [3] Effect of metformin and sulfonylurea on C-reactive protein level in well-controlled type 2 diabetics with metabolic syndrome
    Akbar, DH
    [J]. ENDOCRINE, 2003, 20 (03) : 215 - 218
  • [4] Aljada A, 2004, AM J CLIN NUTR, V80, P51
  • [5] Nuclear factor-κB suppressive and inhibitor-κB stimulatory effects of troglitazone in obese patients with type 2 diabetes:: Evidence of an antiinflammatory action?
    Aljada, A
    Garg, R
    Ghanim, H
    Mohanty, P
    Hamouda, W
    Assian, E
    Dandona, P
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (07) : 3250 - 3256
  • [6] IKK-β links inflammation to obesity-induced insulin resistance
    Arkan, MC
    Hevener, AL
    Greten, FR
    Maeda, S
    Li, ZW
    Long, JM
    Wynshaw-Boris, A
    Poli, G
    Olefsky, J
    Karin, M
    [J]. NATURE MEDICINE, 2005, 11 (02) : 191 - 198
  • [7] Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients
    Bajaj, M
    Suraamornkul, S
    Hardies, LJ
    Pratipanawatr, T
    DeFronzo, RA
    [J]. INTERNATIONAL JOURNAL OF OBESITY, 2004, 28 (06) : 783 - 789
  • [8] Regulation of fasted blood glucose by resistin
    Banerjee, RR
    Rangwala, SM
    Shapiro, JS
    Rich, AS
    Rhoades, B
    Qi, Y
    Wang, J
    Rajala, MW
    Pocai, A
    Scherer, PE
    Steppan, CM
    Ahima, RS
    Obici, S
    Rossetti, L
    Lazar, MA
    [J]. SCIENCE, 2004, 303 (5661) : 1195 - 1198
  • [9] SALICYLATES AS HYPOGLYCEMIC AGENTS
    BARON, SH
    [J]. DIABETES CARE, 1982, 5 (01) : 64 - 71
  • [10] A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
    Belfort, Renata
    Harrison, Stephen A.
    Brown, Kenneth
    Darland, Celia
    Finch, Joan
    Hardies, Jean
    Balas, Bogdan
    Gastaldelli, Amalia
    Tio, Fermin
    Pulcini, Joseph
    Berria, Rachele
    Ma, Jennie Z.
    Dwivedi, Sunil
    Havranek, Russell
    Fincke, Chris
    DeFronzo, Ralph
    Bannayan, George A.
    Schenker, Steven
    Cusi, Kenneth
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (22) : 2297 - 2307